Markets
Bull horns
(Getty Images)

S&P 500 posts fresh closing high as cyclicals shine

The first record close of the month for the benchmark US stock index.

Nia Warfield, Luke Kawa
9/4/25 4:01PM

The S&P 500 set a new closing high with a 0.8% gain, the Nasdaq 100 rose 0.9%, and the Russell 2000 outperformed with a 1.3% advance.

Every S&P sector ETF outside of utilities ended positive on the session, with the cyclical sectors of consumer discretionary, industrials, and financials all up in excess of 1%.

Gains on the day were led by T. Rowe Price and Western Digital, which rose 5.8% and 5.4%, respectively. Centene led declines falling 4.7% after the healthcare company had its price target cut to $33 from $45 by Barclays analysts. Elsewhere...

Amazon rallied 4.3% as the tech titan readies itself to take another stab at the enterprise software market with a new agentic AI tool, according to a report from Business Insider.

Opendoor Technologies soared 16.3% after the company’s president outlined the launch of a community hub to “provide consistent and transparent updates” on the company’s business and source questions from its passionate investor base.

American Eagle shares leapt 38% after the retailer posted blowout Q2 earnings results and reinstated its full-year guidance.

Gap popped nearly 6% after the denim giant said it’s stepping into beauty and accessories, starting with select Old Navy stores this fall and expanding to Gap-branded locations in 2026.

HP Enterprise rose 1.4% as the market continued to digest the enterprise software company’s third-quarter earnings beat late Wednesday.

Meta shares ticked up 1.6% after the social media giant said its Threads app is adding a way for users to post up to 10,000 characters.

Salesforce shares dropped 4.8% after the CRM software company topped Q2 earnings but issued a soft outlook for the current quarter.

Figma shares sank nearly 20% after the design software company reported Q2 results and the likely early release of 25% of the eligible securities owned by certain Figma employees and service providers that are currently under lockup.

JetBlue dipped 6.6% despite the airline saying it now expects operating revenue per available seat mile to fall between 1.5% and 4% in Q3, an improvement from its previous forecast for a 2% to 6% drop.

Texas Instruments fell 4.3% after its chief financial officer reiterated that strength in the chipmaker’s sales through April included a rush to beat potential tariffs and that momentum has slowed since then.

Rivian shares sank 5.1% after the EV maker confirmed it’s laying off workers on its commercial team, with the cuts amounting to less than 1.5% of its workforce.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.